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Abstract 
Synthetic cannabinoid receptor agonists (SCRAs) are suggested to have increased potential 
to induce psychosis compared to natural cannabis (NC). In this review we synthesise current 
knowledge about the association of SCRA use with psychotic symptoms. Following a 
literature search we identified 2 toxicology reports, 4 case-control studies, 3 cross-sectional 
studies and 15 case reports. In each of the case reports, we identified the presence or 
absence of symptoms based on the items of the Postitive and Negative Syndrome Scele 
(PANSS). The toxicology reports highlighted the main presenting features as being toxic 
psychosis and delirium (40%), agitation (10%) and hallucinations (4-7%). The median age 
was 25 years, and around 80% cases were male. Cross-sectional studies reported that SCRA 
use was present in approximately 10-13% patients presenting to acute psychiatric services, 
and was often the cause of their presentation, and that psychotic symptoms were present in  
15% patients attending  emergency departments following SCRA use. Case-control studies 
reported that SCRA use was significantly associated with psychotic symptoms and that SCRA 
users had higher levels of positive psychotic symptoms than NC users. The case reports 
supported the association of SCRA use with a wide range of positive and negative psychotic 
symptoms as well as with self-harm, agitation and aggressive behaviour. SCRA use is 
relatively prevalent in patients with psychosis and may lead to psychotic symptoms in 
individuals with no past psychiatric history.  Further work is required to understand the long 
term risks of SCRA use and optimal management strategies. 
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Introduction 
Since the mid 2000's, new psychoactive substances (NPS) have emerged as a global public 
health concern.  NPS belong to diverse chemical groups and are comprised of substances of 
abuse intended to produce similar effects to existing drugs such as natural cannabis (NC), 
cocaine, heroin, lysergic acid diethylamide (LSD), 3,4-Methyl enedioxy methamphetamine 
(MDMA) and methamphetamine (UNODC, 2017). Of the 739 NPS reported to the United 
Nations Office on Drugs and Crime in 2016, synthetic cannabinoid receptor agonists (SCRA) 
constituted the largest known category, making up 32% of the total number (UNODC, 2017).  
 
NPS use is rare in the United Kingdom, with an estimated 0.4% of the population having used 
them in the last year according to the most recent estimate (ONS, 2017).  Two thirds of NPS 
users reported SCRA use. Despite being used by a relatively small proportion of the 
population, SCRA use is of concern because use is concentrated in vulnerable groups 
(Blackman and Bradley, 2017). There are, however, varying reports on SCRA consumer 
demographics including suggestions that those who abuse the drug are predominantly male, 
previous NC users, homeless or individuals who identify as LGBT (Barratt et al., 2013; 
Manseau et al., 2017; Miller and Stogner, 2014). There is also some evidence to suggest that 
the use of SCRAs is more common amongst the prison and homeless populations (Kalk et al., 
2016). This growing problem is underscored by a recent finding of The Prisons and Probation 
Ombudsman that 19 fatalities over a two and a half year period were highly likely to have 
been proceeded by the use of NPS in UK prisons (HMIP, 2015).  
 
Public health concerns related to SCRAs revolve around potency, with SCRAs having 
significantly higher binding affinity to CB1 and CB2 receptors compared to 
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tetrahydrocannabinol (Wiley et al., 2016). Associated with this is the concern that this higher 
potency may lead to higher risk of toxicity and the potential that use may lead to fatalities 
(UNODC, 2017). Additionally, there continues to be a lack of knowledge regarding the 
contents of substances marketed as synthetic cannabinoids, which can be variable in 
concentration and make-up (UNODC, 2017). Substances such as the synthetic opioid O-
desmethyltramadol, caffeine and the β2-agonist clenbuterol have all been identified in SCRA 
products (Kersten and McLaughlin, 2015). SCRAs are most commonly found in 'herbal' 
mixtures composed of a liquid SCRA solution, which has been dissolved in a solvent and then 
sprayed onto plant material. However, this approach leads to areas of greater SCRA 
concentration (known as ‘hot spots’), which can put users at risk of overdose (Dresen et al., 
2010). Whilst the plant material is intended to be smoked, liquid SCRA solution may also be 
administered via vaporisation (UNODC, 2017). SCRAs are sometimes found in tablet form, as 
a white crystalline solid or powder intended for oral consumption or nasal insufflation 
(UNODC, 2017).    
 
Several recent reviews are available on the adverse clinical effects of SCRAs (Gunderson et 
al., 2012; Tait et al., 2016). Such reviews document an increasing catalogue of adverse effects, 
which are wide ranging and include both physical and psychological manifestations. Briefly, 
SCRA intoxication is dominated by neuropsychiatric, cardiovascular, and abdominal signs, 
with agitation, paranoia, tachycardia, hypertension, abdominal pain and vomiting being 
among the most common (Castaneto et al., 2014; Muller et al., 2017; Vearrier and 
Osterhoudt, 2010).  
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The association between NC use and psychosis has been well documented (Fergusson et al., 
2006). SCRAs are hypothesised to have an increased potential to induce psychosis compared 
to NC, because they have  a higher affinity for the CB1 receptor and act as full agonists (Murray 
et al., 2016). In this review we aim to synthesise current knowledge about the association of 
SCRA consumption with psychotic symptoms – including toxicology data, epidemiological 
studies, case-control studies and case reports. 
 
Experimental Procedures 
In November 2017, English language studies were identified from Ovid MEDLINE (PubMed), 
PsychINFO, PsychArticles, Embase and Google Scholar databases for observational studies 
and case reports related to SCRA use and psychotic symptoms. Search terms included 
(Synthetic Cannabinoid OR Synthetic Marijuana OR Synthetic Cannabis OR Legal High OR Spice 
OR K2) AND (Psychosis OR Schizophrenia). Article reference lists were examined for other 
relevant papers to be included. Only peer-reviewed publications that involved SCRA use in 
humans were considered. Systematic reviews were excluded from abstraction but were hand-
searched as a source of additional material. Case reports were excluded if psychotic 
symptoms were not directly observed by a medical professional and a diagnosis of psychosis 
was not clearly documented. Multiple case reports were also excluded where the number of 
patients within a group presenting with psychosis was unclear. Case reports where patients 
were undergoing a psychotic episode prior to SCRA use were also excluded. The target 
substance was any SCRA, including self-reported and analytically confirmed cases.  We 
included case reports where SCRAs were the only reported substance use, or in the case of 
poly-substance use, where the authors of the case report stated that SCRAs were the primary 
substance involved. 
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Study Selection 
After removal of duplicates, 303 papers were identified and abstracts screened. Of these, 87 
were excluded as they did not report psychotic symptoms or SCRA use. The full text of 
remaining 216 papers was searched, and a further 192 papers excluded due to not fulfilling 
the inclusion criteria (Fig 1). After abstraction and full text screening, a total of 24 articles 
were selected for review: 2 toxicology reports (Monte et al., 2017; Waugh et al., 2016), 4 case-
control studies (Altintas et al., 2016; Bassir Nia et al., 2016; Shalit et al., 2016; Welter et al., 
2017), 3 cross-sectional analyses (Glue et al., 2013; Manseau et al., 2017; Vallersnes et al., 
2016) and 15 case reports (Barcelo et al., 2017; Benford and Caplan, 2011; Coppola and 
Mondola, 2017; Hurst et al., 2011; Johnson et al., 2011; Mahgoub and Young, 2017; Meijer et 
al., 2014; Muller et al., 2017; Oliveira et al., 2017; Oluwabusi et al., 2012; Ozer et al., 2016; 
Roberto et al., 2016; Rojek et al., 2017; Samaan et al., 2016; Van der Veer and Friday, 2011) 
(Figure 1).  
 
In order to summarise the symptoms described in the case reports, we used the Positive and 
Negative Syndrome Scale (PANSS) items (Kay et al., 1987) as a structure for systematically 
analysing the reports. For each item on the PANSS we determined whether related symptoms 
or behaviours were mentioned in the report (i.e. hallucinations, delusions, hostility). If the 
report mentioned a symptom related to a particular PANSS item, then we recorded that item 
as being present, otherwise it was recorded as absent. Thus for a particular case report, a 
score of 1 or 0 could be recorded for each PANSS item.. In addition, the mention of drug-
related suicidal ideation, self-harm, insomnia or amnesia, and any past psychiatric history in 
each report was recorded. 
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Results 
Toxicology Reviews 
Of the nearly 40,000 cases reported to the registry of the national Toxicology Investigators 
Consortium (ToxIC) in the USA between 2010 and 2015, 353 cases were ascribed to SCRA 
toxicity (Monte, A.A., et al, 2017).  Overall SCRA toxicity cases reported to ToxIC follow an 
upward trend, with only 6 reported in 2010 compared to 112 reported in 2015, suggesting a 
growing problem (Monte et al., 2017). In the UK a similar upward trend was observed in the 
510 enquiries related to SCRA exposure dealt with by the National Poisons Information 
Service (NPIS) between 2007 and 2014 (Waugh et al., 2016). Clinical presentation varied with 
the most common s recorded by the ToxIC Registry being agitation in the setting of toxic 
psychosis and delirium, which was seen in 146 (41.4%) patients (Monte et al., 2017). In 
contrast agitation and aggression were only reported in 10.4% of cases reported to the NPIS 
2014 (Waugh et al., 2016). In both the UK and USA hallucinations were less commonly 
reported than agitation, seen in 7.1% of patients in the ToxIC registry and 4.6% of those 
reported to the NPIS (Monte et al., 2017; Waugh et al., 2016). A median age of 25 was 
recorded by both the NPIS and ToxIC registry in regards to SCRA users, with around 80% of 
cases listed as male by both databases (Monte et al., 2017; Waugh et al., 2016). 37% of cases 
received treatment with benzodiazepines, 10% were prescribed antipsychotics and 9% 
received both (Monte et al., 2017). However administration of either class of drugs did not 
seem to reduce the probability of intensive care unit (ICU) admission (Monte et al., 2017). The 
majority of cases reported to ToxIC were seen in the Emergency Department at first 
consultation, with 24% requiring ICU admission and one case resulting in death (Monte et al., 
2017).   
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Cross-sectional analyses 
Manseau and colleagues investigated the demographics of patients attending psychiatric 
emergency services in an urban setting in the USA who had reported SCRA use (Manseau et 
al., 2017). They found that approximately 11% of the patient records that they assessed had 
reports of SCRA use. SCRA users were primarily non-white (90%), male (96%), with a history 
of contact with the police (35%) and homeless (85%). They also often had pre-existing 
psychotic symptoms (70%), a history of a diagnosis of a psychotic disorder (40%), previous 
hospital admission (71%), comorbid substance use (63%), agitation (23%) and the need for 
extended psychiatric observation (16%) and admission (35%). 
 
Glue and colleagues reported SCRA-related admissions to an acute psychiatric ward in New 
Zealand between January and April 2014 (Glue et al., 2013). They reported that 13% of all 
admissions to the ward during this period (17 patients with 21 admissions) were related to K2 
use. For 4 of the patients this was a first admission, and for the remaining 13, a further 4 
presented for the first time with psychotic symptoms. Presenting features included psychotic 
and affective symptoms, as well as suicidal thoughts and behaviour. The mean duration of 
admission was 9 days, although in those with psychotic symptoms it was 13 days. 
 
Vallersnes and colleagues reported data from the European Drug Emergencies Network 
between October 2013 and September 2014 on patients presenting to European emergency 
departments with acute drug toxicity (Vallersnes et al., 2016). They reported that 6.3% of 
attendances included psychotic symptoms. The median age was 29, 79% were male and 32% 
were admitted to a psychiatric ward. More than one drug was taken in 54% of cases. Psychosis 
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was present in 15% of patients who reported taking SCRAs. This compared to 57% on 
tryptamines, 23% on methylphenidate, 21% on LSD, 19% on psilocybe mushrooms, 14% on 
amphetamine and 10% on NC. 
 
Case-control studies 
Bassir and colleagues examined the records of 594 patients who had been admitted to a dual 
diagnosis psychiatric ward in the USA in 1 year (Bassir Nia et al., 2016). They studied the level 
of psychiatric symptoms in patients who had a history of SCRA use or NC use either singly or 
in combination. They found that those who used SCRA had significantly higher levels of 
psychotic symptoms than those who took SCRA and NC together, who in turn had higher 
levels of psychotic symptoms than those who took NC alone. SCRA users had the highest level 
of agitation, and users who took both SCRA and NC had the highest levels of aggression. SCRA 
users were also prescribed higher doses of antipsychotic medication. 
 
Shalit and colleagues studied patients admitted to a psychiatric ward in Israel who reported 
SCRA use and compared them to patients admitted who reported NC but not SCRA use (Shalit 
et al., 2016). The SCRA users were younger than NC users, had longer admissions, and more 
marked psychotic symptoms (PANSS total score of 82.5 vs. 70). 
 
Welter and colleagues reported the prevalence of SCRA use in a psychiatric inpatient 
population in Germany and compared those with a history of NC use to those with a history 
of SCRA use (Welter et al., 2017). They reported that 7% of all psychiatric inpatients under the 
age of 65 had a history of SCRA use (10% of those presenting with psychosis), whereas 43% 
of patients had a history of NC use. SCRA users tended to be younger than NC users (mean 
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age 26 vs. 32), male (71% vs 62%), be on a closed ward (81% vs 42%) and be psychotic on 
admission (71% vs 62%). Analysis of individual symptoms, based on a subset of the PANSS 
scale, reported during acute intoxication showed that NC users had more predominant 
negative symptoms whereas SCRA users had more marked positive symptoms, but the 
reported symptom profiles of the two classes of drug overlapped considerably. 
 
Altintas and colleagues identified 50 patients who had been admitted to a psychiatric ward in 
Turkey following SCRA-induced psychosis (Altintas et al., 2016). They also identified 31 
concurrently hospitalised patients with schizophrenia. The mean age of the SCRA patients was 
29, whereas it was 43 in those with schizophrenia. The average age of first SCRA use was 23. 
Patients with SCRA-induced psychosis had lower PANSS negative scores (18 vs. 22.3), and 
higher HAM-A scores (17.8 vs 11.4). Both groups had similar levels of symptoms on PANSS 
positive scores and Brief Psychiatric Rating Scale (BPRS).  
 
Case Reports 
The case reports were 100% male, with a total of 30 cases. Five of these had a past psychiatric 
history (schizophrenia, bipolar affective disorder, post-traumatic stress disorder, cannabis-
induced psychosis and amphetamine-induced psychosis) (Table 1 and 2). Not all case reports 
gave an age for each individual, but reported ages ranged from 16-66, with most cases being 
in their late teens or early twenties. The largest proportion of case reports were from the USA 
(22 cases), with the remaining 7 cases from Europe and 1 from Turkey. Case reports were 
divided into those that related to patients with a previous psychiatric history (PPH) and those 
with no previous psychiatric history (NPPH). Cases with a past psychiatric history tended to 
be slightly older than those without. There were a large variety of symptoms reported 
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spanning both positive and negative symptom domains. There was generally no clear 
distinction in the range and type of symptoms reported in people with or without a previous 
psychiatric history, although reports of blunted affect were more common in patients without 
any past psychiatric history (Table 3).  
 
There were incidents of self-harm across both groups including substantial burns related to 
one NPPH patient’s paranoid delusions that his own hands were going to harm him (Meijer et 
al., 2014), and one patient who inflicted a penetrating wound to his neck requiring 
otorhinolaryngological surgery in the PPH group (Oliveira et al., 2017). Violent behaviour was 
noted in one NPPH case report resulting in the death of a female relative (Rojek et al., 2017), 
which is consistent with previous reports of homicidal ideation in SCRA users (Glue et al., 2013). 
 
Treatment was generally with second generation antipsychotic drugs, and symptoms resolved 
in most cases within 2 weeks, although relapse occurred in 4 cases where patients restarted 
SCRA or heavy NC use. In two cases where haloperidol was used, the psychotic symptoms did 
not completely resolve within 2 weeks. 
 
 
Discussion 
In this review, we found evidence for the association of SCRA use with psychotic symptoms, 
even in individuals with no past psychiatric history. It is remarkable that the range of 
symptoms reported overlapped very closely with schizophrenia, although one study in which 
symptoms were compared directly revealed that the symptoms were less severe in the SCRA 
group (Altintas et al., 2016). Interestingly, one case series reported that the psychotic 
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symptoms induced by SCRA in patients with schizophrenia were distinct from their existing 
psychotic symptoms (Celofiga et al., 2014).  
 
We found evidence of hostility in 12.3% of cases with NPPH and 40% of cases with PPH. This 
is in keeping with previous reports of hostility associated with SCRA use (Monte et al., 2017; 
Waugh et al., 2016) and reflects reports of increased levels of violence associated with NPS 
(Shafi et al., 2017).  A more recent study of 5 specific SCRA compounds reported aggression 
and agitation in over 80% of patients presenting with intoxication from these substances to 
emergency departments (Hill et al., 2018). 
 
SCRAs were originally developed to mimic the activity of delta-9-tetrahydrocannabinol (Δ9-
THC) (the major psychoactive component of NC), which is a partial agonist of cannabinoid 
receptors CB1 and CB2 (Vardakou et al., 2010). Δ9-THC is thought to account for the 
association between NC and psychosis, whereas cannabidiol is thought to counteract this 
psychotic effect (Hervas, 2017). The findings of Bassir Nia and colleagues that isolated SCRA 
use is associated with psychosis to a greater degree than SCRA and concurrent NC use (or NC 
use alone), may be due to cannabidiol exerting an antipsychotic effect when consumed 
alongside SCRAs, although the relatively low concentration of cannabidiol in modern NC 
makes this less likely (Bassir Nia et al., 2016). Alternatively, the increased psychotogenicity of 
SCRAs may be due to them being high affinity full agonists at CB1 receptors whereas Δ9-THC 
is a partial agonist (Hess et al., 2016; Seely et al., 2012). Indeed, SCRAs can have a potency 
several hundred fold greater than Δ9-THC (Guhring et al., 2001). Furthermore, it appears that 
modifications to existing SCRAs are being made further increase the affinity for the CB1 
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receptor (Gamage et al., 2018), with novel SCRAs showing the highest potency at the CB1 
receptor becoming more commonly available on the market (Marusich et al., 2018). 
 
Due to stronger action at the CB1 receptor, SCRAs are thought to more strongly inhibit GABA 
mediated neurotransmission than Δ9-THC (van Amsterdam et al., 2015). This in turn is thought 
to lead to overactivation of dopaminergic activity in the prefrontal cortex, resulting in 
psychotic symptoms (Bossong and Niesink, 2010). Additionally, a recent MRI study suggests 
that long term use of SCRAs is associated with abnormal white matter integrity, which has 
also been proposed as a theory for the mechanism of vulnerability to psychosis (Zorlu et al., 
2016). 
 
The similarity of positive and negative symptom severity in those experiencing psychosis 
associated with schizophrenia and substance induced psychotic disorder has previously been 
described (Srisurapanont et al., 2011). Indeed, several drug models of schizophrenia have 
been proposed, including Δ9-THC (Carhart-Harris et al., 2013; Steeds et al., 2015). In support 
of this theory, certain alterations in neurophysiological measures occurring in NC 
administration, also take place in patients with schizophrenia (including mismatch negativity, 
P50 suppression and P300 potential) (Gallinat et al., 2012). Likewise cannabidiol has proved 
efficacious against psychotic symptoms in schizophrenia, suggesting that these symptoms 
may be linked to activation of cannabinoid receptors (Leweke et al., 2012).  
 
It is perhaps unsurprising that a young mean age was noted in patients with psychosis who 
are SCRA users, considering that SCRA products tend to be marketed to attract a young 
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demographic (Vardakou et al., 2010). Internationally, peak use appears to occur in the late 
teens and early twenties (Loeffler et al., 2016). 
 
Where stated, medical therapy described in the case reports ranged from antipsychotics 
(haloperidol, risperidone, olanzapine, quetiapine, aripiprazole and amisulpride), to 
benzodiazepines (clonazepam and lorazepam) and mood stabilisers (divalproex). 
Antipsychotic medications exert their effects by antagonising dopamine (D2) receptors (Kapur 
and Mamo, 2003). Neuroscientific studies have identified atypical dopamine activity in NC 
users, which therefore could underlie its association with psychosis in SCRA users (Fergusson 
et al., 2006). Although there are no specific antidotes or treatments for SCRA toxicity, it has 
been suggested that the CB1 receptor antagonist rimonabant (a former treatment for obesity) 
could be an option for the medical management of SCRA overdose (Ford et al., 2017). 
However, due to psychiatric disturbances, rimonabant, was withdrawn by the European 
Medicines Agency in 2008 and clinical research into potential uses has since been suspended. 
 
A major factor in the evolution of SCRAs appears to be a bid to evade the increasing global 
regulation of SCRA production, possession and supply. When first sold, the SCRA Spice, which 
is commonly referred to in the literature and case reports detailed here, was thought to 
consist of JWH-018 and JWH-073 (Seely et al., 2012). Formerly known as ‘legal highs’, the law 
is slowly catching up with NPSs. Following the Psychoactive Substances Act (PSA) of 26 May 
2016, the production and supply of NPS became illegal within the UK (PHE, 2017). With regard 
to the efficacy of PSA as a deterrent to those selling such drugs, one study found that the 
online availability of the SCRA known as 'MDMB-CHMICA' fell from 47 to 38 websites between 
March and June 2016 (Haden et al., 2017). It is possible that SCRA toxicity will undergo a 
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decline in the UK following this change in the legislature, although clinical urine screening for 
SCRAs remains a challenge, which is likely to drive continued use in prison. The National 
Poisons Information Service Report (NPIS) for 2016/2017 noted a 73.2% reduction in 
telephone enquiries related to NPS and a 52.8% reduction in telephone enquiries related to 
SCRAs specifically (PHE, 2017). Additionally, accesses to the TOXBASE database related to 
SCRAs and NPS fell 33.5% and 63.8% respectively. It is however too early to tell if there is a 
causal link between the introduction of the PSA and this fall. It is also very possible that the 
fall itself is due to a drop in self reporting SCRA use to clinicians due a fear of repercussions 
relating to their illegality. 
 
A more recent development involves modifications being made to the first generation 
‘parent’ compounds detailed above. This has resulted in the evolution of three distinct 
generations of SCRAs, with second generation SCRAs including alkyl derivatives, N-
methylpiperidines and benzoylindoles. Third generation SCRAs can be broadly classified into 
molecules where the indole ring has been replaced with an indazole or benzimidazole group, 
where the carbonyl group has been replaced with carboxylic or carboxy-amide functional 
group and quinolones with secondary cyclic structures and new nitrogen groups (Pintori et 
al., 2017). Despite these differences in structure, all SCRAs remain lipid soluble, non-polar and 
highly volatised with a high affinity for CB1 and CB2 receptors (Gamage et al., 2018; Marusich 
et al., 2018; Schoeder et al., 2018; Seely et al., 2012). 
 
It is important to address the limitations of this review. Namely, there are many shortcomings 
when working with case report data. These include the degree of interpretation required 
when eliciting specific symptoms from descriptive and subjective case reports. The method 
 16 
 
of comparing positive and negative symptoms was vulnerable to under-reporting of negative 
symptoms, and it is possible that patients were more likely to be selected for case reports if 
experiencing positive symptoms. Most of the case reports and studies examined for this 
review relied on the use of SCRAs being self-reported by the patient. Previously, a higher rate 
of psychotic disorders has been identified in studies where the presence of the SCRA was 
analytically confirmed, compared to self-report alone (van Amsterdam et al., 2015) and a 
recent emergency services case series found that only half of patients who had taken SCRAs 
reported doing so (Abouchedid et al., 2017). It is therefore possible that the cases that went 
unreported, and therefore were not written up or included in the data, may have provided 
conflicting information to the ones detailed here. 
 
Associated with the problems of self-report is the fact that it is not possible to ascertain which 
particular chemical was taken on each occasion. There is considerable chemical diversity to 
synthetic cannabinoids, with new compounds being developed on an ongoing basis and it is 
not clear how differences in chemical structure might affect the pharmacodynamics profiles 
of these compounds (Fattore and Fratta, 2011). Certain SCRAs may be more available in 
particular areas or countries and so it is not clear how generalizable findings may be (Gol and 
Cok, 2017). 
 
Relatively few studies were found that reported the demographics of psychotic SCRA users. 
Although they reported a similar mean age, small sample sizes dictate that further research 
is needed to confirm that a young demographic is associated with SCRA induced psychosis. 
Despite the lack of evidence however, it may be prudent for the clinician confronted with a 
psychotic patient in their twenties with a negative drug screen to consider the possibility of 
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SCRA involvement, particularly if there is pronounced agitation in combination with increased 
heart and blood pressure, and vomiting.  
 
Conclusion 
Early evidence suggests that SCRAs are associated with psychosis in a young demographic. 
Recent studies also suggest that there is a greater association between SCRAs and psychosis 
than NC and psychosis. Whether SCRA induced psychosis is a growing problem, or changes in 
the law are leading to a decline in SCRA use is unclear. Case reports examined here suggest 
that SCRA users with a previous psychiatric history may present with more positive symptoms 
compared to those with first episode psychosis. However, reliance on case report data is a 
limitation of this review and further case control studies are required to confirm this finding. 
Furthermore, clear treatment guidelines are required for clinicians giving medical care to 
individuals with suspected SCRA induced psychosis.  
 
  
 18 
 
 
Figure 1: Prisma flow diagram of selection of papers.  
Records identified through 
database searching  
(n = 394) 
Sc
re
en
in
g 
In
cl
u
d
ed
 
El
ig
ib
ili
ty
 
Id
en
ti
fi
ca
ti
o
n
 
Additional records identified 
through other sources  
(n = 3) 
Records after duplicates removed  
(n =   303) 
Records screened  
(n = 303) 
Records excluded as not 
relevant  
(n = 87) 
Not Psychosis 
Not SCRA 
Full-text articles assessed 
for eligibility  
(n =  216) 
Full-text articles excluded, 
with reasons  
(n = 192) 
Not peer reviewed 
Animal Study 
Not psychosis 
Not SCRA 
Pharmacology Reviews 
Not English Language 
Not original data 
Studies included in 
qualitative synthesis 
 
Case reports / series 
(n=15) 
Case-control studies  
(n = 4) 
Cross-sectional analysis  
(n= 3) 
Toxicology Reviews 
(n=2) 
 19 
 
 
 20 
 
Table 1: First episode psychosis: Case reports of psychosis induced by SCRA use in patients with no previous history of psychosis 
Study Case(s), 
n: sex, 
age 
Country SCRA Brand 
Name / 
Compound / 
Analysis / 
Duration / 
Evidence of 
polysubstance 
abuse 
Positive 
Symptoms 
Negative 
Symptoms 
General 
Psycho- 
pathology 
Physical 
Signs & 
Symptoms 
Other 
Symptoms 
Treatment / Duration 
/ Length of Stay 
Coppola, 
M. et al, 
2017 
1, male, 
18,  
Italy JWH-122 / Gas 
chromatography 
mass 
spectrometry 
 
Cannabis 
(History of heavy 
daily use).  
 
Hallucinogenic 
mushrooms 
(once). 
Visual 
hallucination 
(coloured 
geometric 
forms and 
animals) 
 
 
 
 
PANNS 
Positive 
symptom 
score 8 
Blunted 
affect 
 
 
 
 
 
 
 
PANNS 
Negative 
symptom 
score 8 
 
Anxiety 
 
Tension 
 
 
 
 
 
 
PANSS 
General 
Psycho-
pathology 
Score 18 
Tachycardia   6 mgs daily of 
clonazepam 
 
Symptoms re-occurred 
for 3 years during heavy 
cannabis use or periods 
of boredom 
 
Monitored regularly for 
a year 
 
Overall PANSS score of 
34 
 
Rojek, 
S., et al, 
2017 
1, male, 
18 
Poland Mr Green – No 
bad trip / AM-
2201 / Gas 
chromatography 
mass 
spectrometry 
 
Cannabis. 
 
Legal Highs. 
Delusions (of 
possession / 
being part of a 
film) 
 
Hostility 
 
Lack of 
spontaneity 
and flow of 
conversatio
n 
Anxiety 
 
Motor 
retardation 
 
Poor impulse 
control 
Dyslalia 
 
Sialorrhea 
 
Wide pupils, 
unresponsive 
to light 
  
Violent 
behaviour - 
murder of a 
female 
relative and 
attempted 
murder of 
two other 
victims by 
stabbing 
Not stated 
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Immature 
personality 
disorder 
 
 
Mahgou
b, N. 
and 
Young, 
R.C., 
2017 
1, male, 
66,  
USA K2 / Self 
reported daily 
use for 2 months 
to self treat back 
pain  
 
Cannabis (use in 
adolescence) 
 
 
Delusions 
(Persecutory) 
  Tachycardia  
 
Hypertension 
 Risperidone (2 mg/d) - 
tapered and 
discontinued after 2 
weeks 
Ozer, U., 
et al, 
2016 
1, male, 
17,   
Turkey Bonzai / Self 
reported use 
most days for 10 
days 
 
Previous volatile 
substance 
abuse. 
Delusions 
(paranoid, 
persecutory -
Capgras 
syndrome 
delusions that 
his parents had 
been replaced) 
 
Auditory 
hallucinations 
 
Suspiciousness 
/ Persecution 
Lack of 
spontaneity 
and flow of 
conversatio
n 
Anxiety 
 
Tension 
 
Reduced 
appetite 
Self-harm 
 
Insomnia 
 
 
Olanzapine 10mg/day – 
complete recovery 
achieved after 2 weeks.  
Meijer, 
K.A., et 
al, 2014 
1, male, 
26 
USA Black Diamond / 
Self reported  
 
Attention deficit 
disorder, treated 
with lis-
dexamfetamine 
dimesylate and 
Delusions 
(Paranoid - 
that his hands 
were going to 
harm him, 
resulting in an 
attempt to 
burn them off 
   Self-harm 
(fourth-
degree 
burns to 
the bilateral 
hands and 
forearms 
with 
Burn resuscitation, 
multiple debridements, 
transradial amputation, 
toe transfer, myoelectric 
prosthesis 
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stable for a 
period of years 
and “get the 
devil out.”) 
second-
degree 
burns to 
the face) 
Samaan, 
J., et al, 
2016 
1, male, 
18 
USA Self report 3-4 
day use of an 
SCRA (and 
abstinence from 
cannabis for 1 
month 
supported by a 
urine screen) 
 
Cannabis  
Delusions 
(Paranoid) 
 
Auditory 
hallucinations 
 
 
 
 
 
Anxiety 
 
Tension 
 
Poor impulse 
control 
Shortness of 
breath 
 
Diaphoresis 
Suicidal 
Ideation 
Antipsychotic regimen  
 
Symptoms subsided 2-3 
weeks after discharge 
Roberto, 
A.J., et 
al, 2016 
1, male, 
18 
USA K2 and Spice / 
Self reported  
 
Cannabis (until 
the previous 3-4 
weeks) 
Delusions 
(Paranoid -
thought 
insertion and 
broadcasting) 
 
Conceptual 
Disorganisatio
n 
 
Auditory 
hallucinations 
(paranoid) 
 
Excitement 
 
Suspiciousness 
/ Persecution 
 
Hostility 
Blunted 
affect  
 
Emotional 
Withdrawal 
 
Poor 
Rapport 
 
Passive/ 
Apathetic 
Social 
Withdrawal 
 
Lack of 
Spontaneity 
and Flow of 
Conversatio
n 
Mannerisms 
and Posturing 
 
Motor 
retardation 
 Insomnia 
 
 
 
 
 
Lorazepam 2 mg orally 
PRN 
 
Oral risperidone, 2 mg in 
the morning and 3 mg at 
night 
 
Two week 
hospitalisation.  
 
Relapse 2 weeks after 
discharge coinciding with 
SCRA use and medicinal 
noncompliance 
Oluwab
usi, 
1, male, 
16 
USA K2 / Self 
reported as 
Delusions 
(Paranoid) 
Passive/ 
Apathetic 
Anxiety 
 
 Insomnia 
 
Quetiapine as an 
inpatient, changed to 
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O.O., et 
al, 2012 
significant and 
frequent  
Cannabis 
(suspected) 
 
Conceptual 
Disorganisatio
n 
 
Visual 
hallucinations, 
Auditory 
hallucinations 
(musical) 
 
Grandiosity 
 
Excitement 
 
Hostility 
 
 
Social 
Withdrawal 
Depression  aripiprazole secondary 
to dystonic reaction. 
 
Relapse coinciding with 
SCRA use after 3 months. 
 
Oral dispersible 
olanzapine 5mg (titrated 
to 15mg). 
Oluwab
usi, 
O.O., et 
al, 2012 
1, male, 
17 
USA K2 / Self 
reported for 1 
month 
Delusions 
(thought 
broadcasting) 
 
Conceptual 
Disorganisatio
n 
Passive/ 
Apathetic 
Social 
Withdrawal 
Somatic 
concern 
 
Anxiety 
 
 
 Insomnia 
 
Olanzapine 15mg at 
night. 
 
Relapse coinciding with 
SCRA use and medicinal 
noncompliance 
Hurst, 
D., et al, 
2011 
10, 
male, 
21-25 
USA SCRA only (2) / 
Self-reported (3 
weeks to 1.5 
years) (10) 
 
Cannabis (8) 
Delusions 
(Paranoid) (9) 
 
Conceptual 
Disorganisatio
n (4) 
 
Visual 
hallucinations 
(2) 
 
Blunted 
affect (6) 
 
Lack of 
Spontaneity 
and Flow of 
Conversatio
n (3) 
 
Anxiety (2) 
 
Motor 
retardation 
(6) 
 
 
Suicidal 
ideation (4) 
 
Insomnia 
(6) 
 
 
Hospitalisations between 
6-10 days 
 
Psychotic symptoms 
resolved (5 days – 5 
months) 
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Auditory 
hallucinations 
(4) 
 
Disorganised 
behaviour (7) 
and speech (6) 
Benford, 
D.M., et 
al, 2011 
1, male, 
20 
USA Spice / Self 
reported 
Visual 
hallucinations 
 
Auditory 
hallucinations 
 
Suspiciousness 
/ Persecution 
Poor 
Rapport 
 
Lack of 
Spontaneity 
and Flow of 
Conversatio
n 
Anxiety Tachycardia 
 
Diaphoretic 
  
Johnson, 
L.A., et 
al, 2011 
1, male, 
23 
USA Spice / Self 
reported / 96 
hours and 48 
hours before 
presentation  
 
Cannabis (3 
years earlier) 
Delusions 
(Paranoid, 
persecutory – 
of being video 
taped) 
 
Conceptual 
Disorganisatio
n 
 
Suspiciousness 
/ Persecution 
 
Disorganised 
behaviour 
 Guilt   Symptoms 
spontaneously resolve 
24 hours after 
presentation 
Van Der 
Veer N 
& Friday 
J., 2011 
1, male, 
20-30 
USA Spice / Self 
reported 3-4 
week history of 
smoking a ‘bowl’ 
of spice daily  
 
Delusions 
(Capgras) 
 
Conceptual 
Disorganisatio
n 
Stereotype
d Thinking 
Inappropriate 
affect 
 
Poor 
attention 
 Suicidal 
Ideation 
Haloperidol 
 
2 week hospitalisation 
(symptoms did not 
resolve completely) 
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Cannabis 
(stopped at time 
of Spice 
initiation) 
Barceló, 
B., et al, 
2017 
3, male 
17 
Spain Spice / Self 
reported 
Delusions (Of 
possession and 
super powers) 
(3) 
 
Grandiosity (3) 
 Anxiety (3) 
 
Tension (3) 
 
Disorientatio
n (3) 
Tachycardia 
(3) 
 
Mydriasis (1) 
Temporary 
Amnesia (3) 
 
Loss of 
Consciousn
ess (3) 
No medical treatment 
required 
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Table 2: Case Reports of psychosis induced by SCRA use in patients with previous history of psychosis 
Study Case(s), 
n: sex, 
age 
Country Psychiatric 
History / 
SCRA Brand 
Name / 
Compound / 
Analysis / 
Duration / 
Polysubstance 
abuse 
Positive 
Symptoms 
Negative 
Symptoms 
General 
Psychopathology 
Symptoms 
Physical 
Signs & 
Symptoms 
Other 
Symptoms 
Treatment / 
Length of Stay 
dos Santos 
Oliveira, 
P.M., et al, 
2017 
1, male, 
32   
Portugal Paranoid 
schizophrenia / 
Diagnosed 9 
years earlier / 
Stable for a 
long period 
 
Shiva 
Ultrastrong 
/ Self-reported 
Delusions  
 
Excitement 
 
Suspiciousness / 
Persecution 
 Anxiety (extreme, 
vegetative) 
 
 
Tachycardia 
 
Mild 
hypotension 
Suicidal 
Ideation 
 
Self harm 
(penetrating 
wound to the 
neck) 
 
Continuation of 
usual 
antipsychotic 
regime 
(monthly IM 
haloperidol 
decanoate 
100mg, 
clozapine 
200mg/day, 
lorazepam 
increased from 
2.5mg OD to 
2.5mg x3/day) / 
ENT surgery 
inpatient 2 
weeks, 
psychiatric 
inpatient 2 
weeks - 
Mahgoub, 
N. and 
1, male, 
65,  
USA Bipolar disorder 
/ history of 
multiple 
Delusions  
 
Grandiosity 
   Manic signs 
and 
symptoms 
Risperidone (6 
mg/d) and 
divalproex 
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Young, 
R.C., 2017 
psychiatric 
admissions 
 
K2 / Self 
reported user 
for previous 
year 
  
Alcohol and 
cocaine 
 
 
 
 
 
(elated 
mood, 
pressured 
speech, 
increased 
energy level, 
decreased 
need for 
sleep) 
(2000 mg/d); his 
serum valproate 
level was 91 
µg/mL after 10 
days on 
medication 
Müller, H., 
et al, 2010 
1, male, 
25 
Germany Cannabis 
induced 
recurrent 
psychotic 
episodes 
 
Spice / Self-
reported 3g on 
3 occasions 
 
Cannabis 
Delusions (of 
manipulation via 
an implanted chip 
in his abdomen) 
 
Visual 
Hallucinations 
(Paranoid) 
 
Auditory 
hallucinations 
(imperative 
voices) 
 Anxiety   Amisulpride 
(800mg/d) for 2 
years 
Van Der 
Veer N & 
Friday J., 
2011  
1, male, 
20-30 
USA Post-Traumatic 
Stress Disorder 
 
Spice / Self 
reported 3-4 
week history 
 
Cannabis 
(stopped at 
time of Spice 
initiation) 
Delusions 
(Paranoid - that 
his phone had 
been bugged and 
there were bullet 
holes in his house) 
 
Conceptual 
Disorganisation 
 
Suspiciousness / 
Persecution 
 
Stereotyped 
Thinking 
Inappropriate affect 
 
Poor attention 
 
 
Suicidal 
Ideation 
 
 
Risperidone 
 
2 week 
hospitalisation 
(symptoms did 
not resolve 
completely) 
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Hostility 
Van Der 
Veer N & 
Friday J., 
2011 
1, male, 
20-30 
USA Amphetamine 
induced prior 
psychotic 
episodes 
 
Spike 99 / NOK 
reported him as 
regular user 
 
Amphetamine 
Delusions 
(Paranoid, 
persecutory – that 
he was from hell) 
 
Conceptual 
Disorganisation 
 
Suspiciousness / 
Persecution 
 
Hostility 
Stereotyped 
Thinking 
Inappropriate affect 
 
Poor attention 
  Haloperidol 
 
2 week 
hospitalisation 
(symptoms did 
not resolve 
completely) 
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Table 3: Percentage of individuals with no previous psychiatric history (NPPH) and those with previous psychiatric 
history (PPH) who experienced specific positive, negative and general psychopathology symptoms. 
 
 
Positive Symptoms 
NPPH % 
(n) 
PPH % 
(n) 
General Psychopathology Symptoms 
NPPH % 
(n) 
PPH % 
(n) 
Delusions  
88.0% 
(22) 
100.0% 
(5) 
Somatic Concern  
4.0%  
(1) 
(0) 
Conceptual Disorganisation  36.0% (9) 40.0% (2) Anxiety  
48.0% 
(12) 
40.0% 
(2) 
Hallucinations     Guilt Feelings 4.0% (1) (0) 
- Auditory 36.0% (9) 20.0% (1) Tension 24.0% (6) (0) 
- Visual 20.0% (5) 20.0% (1) Mannerisms and Posturing 4.0% (1) (0) 
Excitement 8.0% (2) 20.0% (1) Depression 4.0% (1) (0) 
Grandiosity 16.0% (4) 20.0% (1) Motor retardation 32.0% (8) (0) 
Suspiciousness / Persecution 16.0% (4) 60.0% (3) Uncooperativeness (0) (0) 
Hostility 12.0% (3) 40.0% (2) Unusual Thought Content (0) (0) 
Negative Symptoms     Disorientation 12.0% (3) (0) 
Blunted affect 32.0% (8) (0) Poor attention 4.0% (1) 
40.0% 
(2) 
Emotional Withdrawal 4.0% (1) (0) Lack of Judgement and Insight (0) (0) 
Poor Rapport 8.0% (2) (0) Disturbance of Volition (0) (0) 
Passive/ Apathetic Social 
Withdrawal 
12.0% (3) (0) Poor Impulse Control 8.0% (2) (0) 
Difficulty in Abstract Thinking (0) (0) Preoccupation (0) (0) 
Lack of Spontaneity and Flow of 
Conversation 
20.0% (5) (0) Active Social Avoidance (0) (0) 
Stereotyped Thinking 4.0% (1) 40.0% (2)       
Physical Signs     Other Symptoms     
Tachycardia 24.0% (6) 20.0% (1) Insomnia 
40.0% 
(10) 
(0) 
Hypertension 4.0% (1) (0) Suicidal Ideation 24.0% (6) 
40.0% 
(2) 
Hypotension (0) 20.0% (1) Self Harm 8.0% (2) 
20.0% 
(1) 
Diaphoresis 8.0% (2) (0)  Amnesia  12.0% (3) (0)  
      
Mydriasis 4.0% (1) (0) Loss of Consciousness 12.0% (3) (0) 
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